Business Context and Reporting Period
Company: Vaxcyte, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 24, 2025
Event: Entry into a Material Definitive Agreement with Patheon Manufacturing Services LLC (a part of Thermo Fisher Scientific).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new contractual agreement.
Material Changes and Agreement Details
- Counterparty: Patheon Manufacturing Services LLC (Thermo Fisher Scientific).
- Scope of Services: Patheon will formulate, fill, inspect, package, label, test, manufacture, and supply drug product at its Greenville, North Carolina facility.
- Financial Commitments:
- Binding minimum order amounts based on forecast periods at established prices (subject to adjustment).
- Payments for technology transfer activities.
- Reimbursement for certain out-of-pocket capital expenditures.
- Term: Initial term of 15 years from the Effective Date (September 24, 2025), with automatic three-year renewals unless notice of non-renewal is provided.
- Termination Penalties:
- Termination for Convenience: Company must pay the greater of a fixed dollar amount in the mid-eight-figures or an amount based on the then-current binding forecast, plus capital expenditure commitments.
- Program Failure: Company must pay agreed-upon amounts based on a formula.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates a strategic commitment to long-term manufacturing capacity through a 15-year partnership. The full text of the agreement will be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2025.
Risks and Contingencies:
- Financial Liability: Significant termination costs (mid-eight-figures) if the agreement is ended for convenience.
- Operational Dependency: Reliance on a single facility in Greenville, North Carolina, for critical drug product manufacturing.
- Binding Forecasts: Obligation to order minimum amounts based on forecasts, which may create inventory or cash flow pressure if demand shifts.
Investor Verification Checklist
- Verify the specific "mid-eight-figures" termination fee amount in the full agreement text (exhibit to upcoming 10-Q).
- Review the binding forecast periods and minimum order quantities to assess future cash outflow requirements.
- Confirm the status of technology transfer activities and associated costs.
- Monitor the upcoming Form 10-Q for the quarter ended September 30, 2025, for the complete agreement text and any updated financial impact analysis.